The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
P. A. Cohen
Research Funding - VentiRx
D. W. Northfelt
Research Funding - VentiRx
G. J. Weiss
Research Funding - VentiRx
D. D. Von Hoff
Research Funding - VentiRx
K. Manjarrez
Employment or Leadership Position - VentiRx
Stock Ownership - VentiRx
G. Dietsch
Employment or Leadership Position - VentiRx
Stock Ownership - VentiRx
R. M. Hershberg
Employment or Leadership Position - VentiRx
Stock Ownership - VentiRx
R. K. Ramanathan
Research Funding - VentiRx